You are here
HUMANETICS CORP
UEI: MSRQYLLQLYQ5
# of Employees: 7
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Development of BIO 300 as a novel treatment for idiopathic pulmonary fibrosis
Amount: $298,474.00Project Summary Idiopathic pulmonary fibrosis (IPF) is a serious lung disease characterized by progressive scarring of the tissue in the lungs. IPF is associated with a particularly poor prognosis wit ...
SBIRPhase I2023Department of Health and Human Services National Institutes of Health -
Protecting Cardiomyocytes from Mixed Fields of Radiation by BIO 300
Amount: $124,693.00The cumulative dose of radiation exposure to our astronauts remains one of the limiting roadblocks to longer duration missions in space. Humanetics Corporation (Humanetics) is developing a novel radi ...
SBIRPhase I2017National Aeronautics and Space Administration -
Development of BIO as a MCM for lethal radiation pneumonitis fibrosis
Amount: $597,055.00Project Summary A significant need exists for effective medical countermeasures for radiation induced pneumonitis and pulmonary fibrosis associated with the delayed effects of acute radiation exposure ...
SBIRPhase I2016Department of Health and Human Services National Institutes of Health -
Prevention of erectile dysfunction following prostate cancer radiotherapy
Amount: $224,891.00DESCRIPTION (provided by applicant): The aim of this proposal is to evaluate BIO 300 as an effective therapy to prevent and/or mitigate the erectile dysfunction (ED) that is commonly observed fol ...
STTRPhase I2014Department of Health and Human Services National Institutes of Health -
EXERCISE PHASE II TITLE: DEVELOPMENT OF BIO 300 AS A RADIATION MODULATOR FOR USE DURING RADIOTHERAPY OF LUNG CANCER
Amount: $1,499,181.00Lung cancer is the most common cause of cancer-related deaths in the United States. Humanetics will develop BIO 300 as a drug that can be given with radiotherapy for lung cancer to help improve effica ...
SBIRPhase II2014Department of Health and Human Services National Institutes of Health -
IGF::OT::IGF OTHER FUNCTIONS RandD- MEDICAL: BIOMEDICAL (BASIC RESEARCH)
Amount: $197,224.00Lung cancer is the most common cause of cancer-related deaths in the United States. Humanetics will develop BIO 300 as a drug that can be given with radiotherapy for lung cancer to help improve effica ...
SBIRPhase I2012Department of Health and Human Services National Institutes of Health -
Development of Cysteamine as a Medical Radiation Countermeasure
Amount: $600,000.00DESCRIPTION (provided by applicant): The detonation by a terrorist of an improvised nuclear device would expose hundreds of thousands of citizens to acute radiation syndrome (ARS), which untreated lea ...
SBIRPhase I2009Department of Health and Human Services National Institutes of Health
